interferon-alpha-2a
Phase 3Small molecule
Rocheinterferon-alpha-2a is one of 77 small molecule programs targeting Melanoma. It is currently in Phase 3.
2
Indications
6
Total Trials
0
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Libtayo
RegeneronPhase 3
Eylea
RegeneronPhase 3
ABI-007
Bristol-Myers SquibbPhase 3
Fotemustine
RochePhase 3
Interferon Alfa
PfizerPhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
interferon-alpha-2a
RochePhase 3
High-Dose Recombinant Interferon A-2b
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Treatment2 trials
Renal Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for interferon-alpha-2a. EMBL-EBI & Wellcome Sanger Institute.
- [4]